Jianmin Pharmaceutical Group Co Ltd (SHG:600976) — Market Cap & Net Worth
Market Cap & Net Worth: Jianmin Pharmaceutical Group Co Ltd (600976)
Jianmin Pharmaceutical Group Co Ltd (SHG:600976) has a market capitalization of $632.78 Million (CN¥4.32 Billion) as of June 22, 2026. Listed on the SHG stock exchange, this China-based company holds position #11214 globally and #3183 in its home market, demonstrating a 4.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jianmin Pharmaceutical Group Co Ltd's stock price CN¥28.19 by its total outstanding shares 153398600 (153.40 Million). Review Jianmin Pharmaceutical Group Co Ltd debt and liabilities to assess the company's total debt and financial obligations.
Jianmin Pharmaceutical Group Co Ltd Market Cap History: 2015 to 2026
Jianmin Pharmaceutical Group Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $697.14 Million to $632.78 Million (0.82% CAGR).
Jianmin Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jianmin Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.22x
Jianmin Pharmaceutical Group Co Ltd's market cap is 0.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.09x
Jianmin Pharmaceutical Group Co Ltd's market cap is 2.09 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $663.13 Million | $2.36 Billion | $64.66 Million | 0.28x | 10.26x |
| 2017 | $490.68 Million | $2.71 Billion | $90.78 Million | 0.18x | 5.41x |
| 2018 | $299.97 Million | $2.16 Billion | $81.22 Million | 0.14x | 3.69x |
| 2019 | $377.87 Million | $2.24 Billion | $91.49 Million | 0.17x | 4.13x |
| 2020 | $545.99 Million | $2.46 Billion | $147.79 Million | 0.22x | 3.69x |
| 2021 | $1.71 Billion | $3.30 Billion | $305.26 Million | 0.52x | 5.61x |
| 2022 | $1.10 Billion | $3.64 Billion | $408.08 Million | 0.30x | 2.69x |
| 2023 | $1.46 Billion | $4.21 Billion | $521.46 Million | 0.35x | 2.81x |
| 2024 | $935.59 Million | $3.50 Billion | $362.18 Million | 0.27x | 2.58x |
| 2025 | $753.55 Million | $3.35 Billion | $359.84 Million | 0.22x | 2.09x |
Competitor Companies of 600976 by Market Capitalization
Companies near Jianmin Pharmaceutical Group Co Ltd in the global market cap rankings as of June 22, 2026.
Key companies related to Jianmin Pharmaceutical Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
Jianmin Pharmaceutical Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Jianmin Pharmaceutical Group Co Ltd's market cap moved from $697.14 Million to $ 632.78 Million, with a yearly change of 0.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥632.78 Million | -16.03% |
| 2025 | CN¥753.55 Million | -19.46% |
| 2024 | CN¥935.59 Million | -36.12% |
| 2023 | CN¥1.46 Billion | +33.32% |
| 2022 | CN¥1.10 Billion | -35.82% |
| 2021 | CN¥1.71 Billion | +213.51% |
| 2020 | CN¥545.99 Million | +44.49% |
| 2019 | CN¥377.87 Million | +25.97% |
| 2018 | CN¥299.97 Million | -38.87% |
| 2017 | CN¥490.68 Million | -26.01% |
| 2016 | CN¥663.13 Million | -4.88% |
| 2015 | CN¥697.14 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Jianmin Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $632.78 Million USD |
| MoneyControl | $632.78 Million USD |
| MarketWatch | $632.78 Million USD |
| marketcap.company | $632.78 Million USD |
| Reuters | $632.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jianmin Pharmaceutical Group Co Ltd
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells traditional Chinese medicines and paediatric products in China. It provides over-the-counter, medical, and general health products in the form of capsules, granules, and gels under the Jianmin, Longmu, and Yekaitai brands. The company was founded in 1637 and is based in Wuhan, China.